Maxcyte MXCT
NASDAQ MXCT
$1.39 +0.00 (+0.00%)
At close: Aug 20, 2026 · 1:47 PM UTC

Maxcyte (MXCT) Non-Current Debt (2020)

Maxcyte (MXCT) posted quarterly Non-Current Debt of $4.9 million for Q4 2020.

Maxcyte (MXCT) Non-Current Debt (2020) Analysis & Trends

Maxcyte (MXCT) has reported Non-Current Debt for 1 consecutive years, with $4.9 million the latest figure, recorded in Q4 2020.

  • In Q4 2020, Non-Current Debt changed N/A year-over-year to $4.9 million; the TTM figure through Dec 2020 stood at $4.9 million (changed N/A YoY), while the FY2020 annual figure was $4.9 million, changed N/A from the prior year.
  • Non-Current Debt held at $4.9 million in Q4 2020 per MXCT's latest filing.
  • Across five years, Non-Current Debt topped out at $4.9 million in Q4 2020 and bottomed at $4.9 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Abbott Laboratories 199.20 Bn 193.60 Bn 7.27 Bn 29.60 Bn
2 Stryker 127.66 Bn 124.19 Bn 4.50 Bn 14.19 Bn
3 Medtronic 118.98 Bn 109.76 Bn 6.41 Bn 26.17 Bn
4 Boston Scientific 73.25 Bn 72.71 Bn 3.85 Bn 10.92 Bn
5 Edwards Lifesciences 51.93 Bn 47.68 Bn 1.35 Bn 598.70 Mn
6 Dexcom 34.37 Bn 32.42 Bn 830.00 Mn -
7 GE HealthCare Technologies 33.89 Bn 31.78 Bn 2.18 Bn 10.09 Bn
8 Koninklijke Philips 26.36 Bn 23.04 Bn 4.55 Bn 7.34 Bn
9 Steris 23.03 Bn 22.55 Bn 684.20 Mn 1.65 Bn
10 Maxcyte 148.48 Mn 148.48 Mn 5.60 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2020 4.92 Mn